Citi analyst Yigal Nochomovitz raised the firm’s price target on Ovid Therapeutics to $2.50 from $2 and keeps a Neutral rating on the shares. The analyst updated the model to reflect the Q4 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OVID:
- Ovid Therapeutics expects cash to provide runway into 1H25
- Ovid Therapeutics reports Q4 EPS (16c), consensus (18c)
- Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
- Ovid Therapeutics confirms no deposits, accounts at Silicon Valley Bank
- Ovid Therapeutics announces publication of studies of OV350